To evaluate the efficacy and safety of ultrasound-guided percutaneous transhepatic microwave ablation in the treatment of liver cancer.
Methods:
Retrospective analysis of 35 cases (49 lesions) of primary or metastatic liver cancer treated by ultrasound- guided microwave ablation in Taicang First People's Hospital from Apr. 2015 to Jan. 2020
regular postoperative follow-up of contrast-enhanced ultrasonography (CEUS) and hepatic function (ALT) were performed to evaluate the therapeutic effect and liver injury
and to observe the complications.
Results:
All the lesions were completely inactivated by CEUS after operation. The results of follow-up showed that there was no recurrence in the liver at 3 months. There were 2 cases with recurrence of the original ablation site at 6 months
and no new cases at 9 months and 12 months. ALT increased significantly at 1 week after operation (
P
<0.05)
and decreased to the same level at 1 month and 3 months after operation (
P
>0.05). The complications of ablation included 1 case was stopped during operation due to pain
rest for 5 min; 15 cases had slight discomfort in incision or right upper abdomen; 23 cases had fever within 1 week after operation; 3 cases had small pleural effusion after operation; 1 case of postoperative abdominal hemorrhage.
Conclusion:
Ultrasound-guided percutaneous microwave ablation is a safe and effective method for the treatment of liver cancer. It is worthy of clinical application.